YL217 will enter phase 1 before Sotio's similarly acting rival, licensed from Biocytogen.
ApexOnco Front Page
Recent articles
While Sutro shows why it’s shelved luvelta-T.
Akeso’s data look impressive, but perhaps not impressive enough to sustain Summit’s valuation.
The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.
The depressed company could use Mylotarg as a stepping stone in AML.
After Niagara the company faces three pivotal catalysts; none is a slam-dunk.
The group eyes a broader use than Immunocore’s Kimmtrak.
An accelerated approval looks off the table, as the group’s first-line melanoma trial continues.